Conv. Plasma
Nigella Sativa
Peg.. Lambda

All HCQ studies
Meta analysis
Home COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 8% Improvement Relative Risk HCQ for COVID-19  Núñez-Gil et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 954 patients in multiple countries Lower mortality with HCQ (p=0.005) Núñez-Gil et al., Intern. Emerg. Med., Nov 2020 Favors HCQ Favors control

Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry

Núñez-Gil et al., Intern. Emerg. Med., doi:10.1007/s11739-020-02543-5
Nov 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective database study of 1,021 patients in Ecuador, Germany, Italy, and Spain, showing HCQ propensity score adjusted mortality odds ratio aOR 0.88, p=0.005.
risk of death, 7.9% lower, RR 0.92, p = 0.005, treatment 200 of 686 (29.2%), control 100 of 268 (37.3%), adjusted per study, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Núñez-Gil et al., 9 Nov 2020, retrospective, database analysis, multiple countries, peer-reviewed, median age 68.0, 49 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry
Iván J Núñez-Gil, Cristina Fernández-Pérez, Vicente Estrada, Víctor M Becerra-Muñoz, Ibrahim El-Battrawy, Aitor Uribarri, Inmaculada Fernández-Rozas, Gisela Feltes, María C Viana-Llamas, Daniela Trabattoni, Javier López-País, Martino Pepe, Rodolfo Romero, Alex F Castro-Mejía, Enrico Cerrato, Thamar Capel Astrua, Fabrizio D’ascenzo, Oscar Fabregat-Andres, José Moreu, Federico Guerra, Jaime Signes-Costa, Francisco Marín, Danilo Buosenso, Alfredo Bardají, Sergio Raposeiras-Roubín, Javier Elola, Ángel Molino, Juan J Gómez-Doblas, Mohammad Abumayyaleh, Álvaro Aparisi, María Molina, Asunción Guerri, Ramón Arroyo-Espliguero, Emilio Assanelli, Massimo Mapelli, José M García-Acuña, Gaetano Brindicci, Edoardo Manzone, María E Ortega-Armas, Matteo Bianco, Chinh Pham Trung, María José Núñez, Carmen Castellanos-Lluch, Elisa García-Vázquez, Noemí Cabello-Clotet, Karim Jamhour-Chelh, María J Tellez, Antonio Fernández-Ortiz, Carlos Macaya
Internal and Emergency Medicine, doi:10.1007/s11739-020-02543-5
Recently the coronavirus disease (COVID-19) outbreak has been declared a pandemic. Despite its aggressive extension and significant morbidity and mortality, risk factors are poorly characterized outside China. We designed a registry, HOPE COVID-19 (NCT04334291), assessing data of 1021 patients discharged (dead or alive) after COVID-19, from 23 hospitals in 4 countries, between 8 February and 1 April. The primary end-point was all-cause mortality aiming to produce a mortality risk score calculator. The median age was 68 years (IQR 52-79), and 59.5% were male. Most frequent comorbidities were hypertension (46.8%) and dyslipidemia (35.8%). A relevant heart or lung disease were depicted in 20%. And renal, neurological, or oncological disease, respectively, were detected in nearly 10%. Most common symptoms were fever, cough, and dyspnea at admission. 311 patients died and 710 were discharged alive. In the death-multivariate analysis, raised as most relevant: age, hypertension, obesity, renal insufficiency, any immunosuppressive disease, 02 saturation < 92% and an elevated C reactive protein (AUC = 0.87; Hosmer-Lemeshow test, p > 0.999; bootstrap-optimist: 0.0018). We provide a simple clinical score to estimate probability of death, dividing patients in four grades (I-IV) of increasing probability. Hydroxychloroquine (79.2%) and antivirals (67.6%) were the specific drugs most commonly used. After a propensity score adjustment, the results suggested a slight improvement in mortality rates (adjusted-OR hydroxychloroquine 0.88; 95% CI 0.81-0.91, p = 0.005; adjusted-OR antiviral 0.94; 95% CI 0.87-1.01; p = 0.115). COVID-19 produces important mortality, mostly in patients with comorbidities with respiratory symptoms. Hydroxychloroquine could be associated with survival benefit, but this data need to be confirmed with further trials. Trial Registration: NCT04334291/EUPAS34399.
Author contributions ING, CFS and VE designed and analyzed the data. ING, CFS, VE, AFO, CM drafted the manuscript. All of the other collaborators lead the registry in their respective centers and enrolled patients. The order of authorship was determined upon recruitment and HOPE involvement. Finally, all authors had full access to the manuscript and agree with it. Funding Non-conditioned grant (FUNDACIÓN INTERHOSPITA-LARIA PARA LA INVESTIGACIÓN CARDIOVASCULAR, FIC. Madrid, Spain). This nonprofit institution had no role in the study design; in the collection, analysis, interpretation of data; in the writing of the report; nor in the decision to submit the paper for publication. Compliance with ethical standards Conflict of interest The author(s) declare that they have no conflict of interest. Statements on human and animal rights Our study was performed in accordance with the ethical standards of our institutional (Hospital Clinico San Carlos, Spain) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent Written informed consent was waived by a central ethics committee, considering this an anonymized observational study in a pandemic situation.
Cao, Wang, Wen, Liu, Wang, A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19, N Engl J Med
Cheng, Luo, Wang, Zhang, Wang et al., Kidney disease is associated with in-hospital death of patients with COVID-19, Kidney Int
Collaborationncdrf, Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants, Lancet
Collins, Reitsma, Altman, Group, Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. The TRIPOD Group, Circulation
Cortegiani, Ingoglia, Ippolito, Giarratano, Einav, A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19, J Crit Care
Dong, Du, Gardner, Aninteractive web-baseddash-boardtotrackCOVID-19 in real time, LancetInfectDis
Emami, Javanmardi, Pirbonyeh, Akbari, Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis, Arch AcadEmerg Med
Guan, Ni, Hu, Liang, Ou et al., Clinicalcharacteristics of coronavirus disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Iván, Núñez, Alex, Viana-Llamas 7 • Daniela Trabattoni 8 • Javier López-País 9 • Martino Pepe 10 • Rodolfo Romero 11
Lee, Silverman, Bargman, The role of antimalarial agents in the treatment of SLE and lupus nephritis, Nat Rev Nephrol
Li, Yang, Zhao, Zhi, Wang et al., Prevalence and impact of cardiovascular metabolicdiseaseson-COVID-19 in China, Clin Res Cardiol
Louie, Acosta, Winter, Jean, Gavali et al., Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California, JAMA
Mehta, Mcauley, Brown, Sanchez, Tattersall et al., COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet
Nie, Zhang, Jee, Jung, Li et al., Obesity survival paradox in pneumonia: a meta-analysis, BMC Med
Onder, Rezza, Brusaferro, Case-fatalityrate and characteristics of patientsdying in relationtoCOVID-19 in Italy, JAMA
Oudit, Kassiri, Jiang, Liu, Poutanen et al., SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS, Eur J Clin-Investig
Ritchie, Singanayagam, Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?, Lancet
Shi, Qin, Shen, Cai, Liu et al., Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan. China, JAMA Cardiol
Smits, De Lang, Van Den Brand, Leijten, Van Ijcken et al., Exacerbatedinnate host response toSARS-CoV in aged non-human primates, PLoSPathog
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wang, Du, Zhu, Cao, An et al., Comorbidities and multi-organ injuries in the treatment of COVID-19, Lancet
Who, None
Who, None
Who, WHO statement regarding cluster of pneumonia cases in Wuhan
Wu, Mcgoogan, Characteristics of and importantlessonsfromthe coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases fromtheChinese Center forDisease Control and Prevention, JAMA
Yang, Zheng, Gou, Pu, Chen et al., Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis, Int J Infect Dis
Yao, Li, He, Ping, Liu et al., A pathological report of three COVID-19 cases by minimally invasive autopsies, Zhonghua Bing Li XueZaZhi
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop